Drug Search Results
More Filters [+]

Avacincaptad pegol

Alternative Names: avacincaptad pegol, Zimura
Latest Update: 2024-05-14
Latest Update Note: Clinical Trial Update

Product Description

Avacincaptad pegol, a polyethylene glycol-conjugated oligonucleotide, is a potent C5 inhibitor delivered via a 100 µl intravitreal injection.  (Sourced from: https://iovs.arvojournals.org/article.aspx?articleid=2772902)

Mechanisms of Action: C5 Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Injection

FDA Designation:
Breakthrough Therapy - Geographic Atrophy
Fast Track - Geographic Atrophy|Macular Degeneration
Priority Review - Geographic Atrophy *

Approval Status: Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: IVERIC bio
Company Location: NEW YORK NY 10001
Company CEO: Glenn P. Sblendorio
Additonal Commercial Interests: DelSiTech

Clinical Description

Map of Global Clinical Trials for Avacincaptad pegol

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Estonia, France, Germany, Hungary, Israel, Italy, Latvia, Poland, Spain, United Kingdom, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Geographic Atrophy|Macular Degeneration

Phase 2: Stargardt Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

STGD1

P2

Active, not recruiting

Macular Degeneration|Stargardt Disease

2025-04-30

24%

STGD1

P2

Active, not recruiting

Macular Degeneration|Stargardt Disease

2025-04-30

24%

GATHER2

P3

Active, not recruiting

Macular Degeneration|Geographic Atrophy

2025-03-31

42%

GATHER2 OLE

P3

Active, not recruiting

Geographic Atrophy

2025-03-21

Complement C5 Inhibitor

P3

Completed

Macular Degeneration|Geographic Atrophy

2022-07-25

Recent News Events